Research Topics
| M R D'AndreaSummaryAffiliation: Johnson and Johnson Pharmaceutical Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammationRicardo Saban
Department of Physiology, The University Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
BMC Physiol 7:4. 2007..We hypothesize that PARs may link mast cell-derived proteases to bladder inflammation and, therefore, play a fundamental role in the pathogenesis of cystitis...- Regulatory network of inflammation downstream of proteinase-activated receptorsRicardo Saban
Department of Physiology, The University Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
BMC Physiol 7:3. 2007..coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency... 
Add Alzheimer's disease to the list of autoimmune diseasesMichael R D'Andrea
Johnson and Johnson Pharmaceutical, Research and Development, Drug Discovery, Spring House, PA 19477 0776, USA
Med Hypotheses 64:458-63. 2005..Hence, these observations suggest autoimmunity-induced cell death in AD...- Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neuronsMichael R D'Andrea
Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Spring House, Pennsylvania, 19477, USA
Curr Pharm Des 12:677-84. 2006.... - The microglial phagocytic role with specific plaque types in the Alzheimer disease brainMichael R D'Andrea
Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, D404, Spring House, PA 19477, USA
Neurobiol Aging 25:675-83. 2004..In summary, the data presented suggests that plaque associated microglial activation is typically subsequent to specific amyloid plaque formations in the AD brain... - Evidence linking neuronal cell death to autoimmunity in Alzheimer's diseaseMichael R D'Andrea
Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Spring House, PA 19477 0776, USA
Brain Res 982:19-30. 2003..Thus, the presence of +Ig-neurons in AD brains implies a critical link between the faulty BBB and neuronal death through an autoimmune mechanism... - The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observationsMichael R D'Andrea
Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Welsh and McKean Roads, Spring House, PA 19477 0776, USA
Neurosci Lett 342:114-8. 2003..The obvious benefits of formic acid for increasing the sensitivity of amyloid plaque immunolabeling may artifactually emphasize plaques over amyloid-containing cells during analyses... - Collagenase predigestion on paraffin sections enhances collagen immunohistochemical detection without distorting tissue morphologyM R D'Andrea
Johnson and Johnson Pharmaceutical Research and Development, Drug, Discovery, Spring House, PA 19477, USA
Biotech Histochem 79:55-64. 2004..This new use of collagenase for immunohistochemistry promotes increased collagen immunolabeling, is easy to use, is versatile, and allows preservation of tissue structure that provides maximal and accurate histological information... 
PCNA indexing as a preclinical immunohistochemical biomarker for testicular toxicityM R D'Andrea
Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania, USA
Biotech Histochem 83:211-20. 2008..The assay has potential utility as an in vivo biomarker for detecting early testicular toxicity of experimental compounds in preclinical development as well as for refining follow-up compounds with reduced testicular toxicity...- Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysisMichael R D'Andrea
Drug Discovery, D404, Johnson and Johnson Pharmaceutical Research and Development, L L C, P O Box 776, Welsh and McKean Roads, Spring House, PA 19477 0776, USA
Mol Cancer Ther 4:1198-204. 2005..In addition to this specific application of this in vivo validation approach to those targets that use PLCgamma as a downstream signaling partner, these methods may also benefit other drug discovery targets... - Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's diseaseM R D'Andrea
The R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477, USA
Histopathology 38:120-34. 2001..We have investigated the possibility of a link between these two apparently conflicting observations... - Altered vascular injury responses in mice deficient in protease-activated receptor-1W M Cheung
Drug Discovery, The R W Johnson Pharmaceutical Research Institute, Spring House, PA 19477, USA
Arterioscler Thromb Vasc Biol 19:3014-24. 1999..These data suggest that PAR-1(-/-) may play a role in vascular injury responses in this mouse model via possible effects on extracellular matrix regulation... - beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathologyH Y Wang
R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477 0776, USA
J Biol Chem 275:5626-32. 2000.... - Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid arteryB P Damiano
Drug Discovery, The R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477, USA
Thromb Haemost 81:808-14. 1999..Possible functional consequences of this receptor upregulation and its role in the response to vascular injury remain to be determined... - MAP-2 immunolabeling can distinguish diffuse from dense-core amyloid plaques in brains with Alzheimer's diseaseM R D'Andrea
The R W Johnson Pharmaceutical Research Institute, Drug Discovery, Spring House, Pennsylvania 19477, USA
Biotech Histochem 77:95-103. 2002..Furthermore, this biochemical distinction indicates that dense-core and diffuse plaques are formed by different mechanisms... - Simultaneous PCNA and TUNEL labeling for testicular toxicity evaluation suggests that detection of apoptosis may be more sensitive than proliferationM R D'Andrea
Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania, USA
Biotech Histochem 85:195-204. 2010.... - Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer's disease pathogenesisM R D'Andrea
Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
Biotech Histochem 85:133-47. 2010.... - Abnormal patterns of microtubule-associated protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson's disease substantia nigra brain tissuesM R D'Andrea
The R W Johnson Pharmaceutical Research Institute, Welsh and McKean Roads, Spring House, PA 19477, USA
Neurosci Lett 306:137-40. 2001..These PD-associated alterations in MAP-2 morphology and distribution suggest that impaired neuronal transport may contribute to the progression of neuronal loss in the brains of PD patients... - Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in ratsP Andrade-Gordon
Drug Discovery, The R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477 0776, USA
J Pharmacol Exp Ther 298:34-42. 2001..From these results, it is evident that a PAR-1 antagonist is not especially effective for treating platelet-dependent thrombosis; however, it could well be beneficial for treating restenosis attendant to arterial injury... - Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway diseaseS M Belkowski
Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477, USA
Clin Exp Allergy 39:1179-86. 2009..Previously, we demonstrated that chymase is able to cleave SLPI and that the cleaved portion, cSLPI, is a biomarker of chymase activity...